Earnings Releases·Nov 9, 2026, 4:04 PM ET

Septerna — Third Quarter 2026 Earnings Summary

Revenue declined to $18.9 million from $21.5 million in the prior year period, driven by a shift to a net loss of $26.6 million compared to $8.2 million in net income previously, as R&D and G&A expenses rose to $36.6 million and $9.6 million respectively.
The company maintains a strong liquidity position with $565.2 million in cash and marketable securities, providing a runway to fund operations through mid-2029.
Key pipeline milestones are scheduled for Q1 2027, including Phase 1 data release for SEP-479 and the initiation of a Phase 1 trial for the newly selected candidate SEP-204.
Strategic progress includes the appointment of Rajiv Patni, M.D., as Chief Medical Officer and continued advancement of the Novo collaboration, which has generated $13 million in research milestones to date.